Earningsreport
Q1/2024 3/31/2024 EPS 0.710 ZacksConsensus 0.370 ActVsEst 0.340 - Beat
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting [Yahoo! Finance][Yahoo! Finance]
- New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting[PR Newswire]
- BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year [Yahoo! Finance][Yahoo! Finance]
- 4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market [Yahoo! Finance][Yahoo! Finance]
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $115.00 to $112.00. They now have an "overweight" rating on the stock.[MarketBeat]
- More
BMRN
SEC Filings
SEC Filings
- 5/7/24 - Form 4
- 5/6/24 - Form 4
- 5/6/24 - Form 4
- BMRN's page on the SEC website
- More